Infections of humans and livestock with African trypanosomes are treated with drugs 23 introduced decades ago that are not always fully effective and often have severe 24 side effects. Here, the trypanosome haptoglobin-haemoglobin receptor (HpHbR) has 25 been exploited as a route of uptake for an antibody-drug conjugate (ADC) that is 26 completely effective against Trypanosoma brucei in the standard mouse model of 27 infection. Recombinant human anti-HpHbR monoclonal antibodies were isolated and 28 shown to be internalised in a receptor-dependent manner. Antibodies were 29 conjugated to a pyrrolobenzodiazepine (PBD) toxin and killed T. brucei in vitro at 30 picomolar concentrations. A single therapeutic dose (0.25 mg/kg) of a HpHbR 31 antibody-PBD conjugate completely cured a T. brucei mouse infection within 2 days 32 with no re-emergence of infection over a subsequent time course of 77 days. These 33 experiments provide a demonstration of how ADCs can be exploited to treat 34 protozoal diseases that desperately require new therapeutics. 35 36 Author Summary 37
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trypanosome cells. Entry of TLF1 via the HpHbR and the release of a cytotoxin after 96 internalisation is analogous to the mode of action of ADCs (20), a growing class of 97 therapeutics, particularly used in applications in oncology (21) (22) (23) and also with 98 demonstrated potential as anti-bacterials (24, 25 ). An early attempt to develop ADCs 99 against the intracellular American trypanosome, Trypanosoma cruzi, used 100 chlorambucil conjugated to polyclonal IgGs purified from chronically infected rabbits 101 (26) and, while results were promising, this was only partially successful. More 102 recently, antibody therapeutics against African trypanosomes based on single 103 domain antibodies derived from camelid immunoglobulins (nanobodies) recognising 104 some, but not all, VSGs (27, 28) have also been developed. One study used a 105 nanobody apoL-1 fusion protein that was curative in mouse infections(29). In another 106 two studies, nanobodies were used to create nanoparticles containing pentamidine, 107 one of the current drugs used to treat trypanosome infection. These particles bound 108 VSG and were successfully taken up into the endocytic pathway, the concentration 109 required for cure was 10 to 100-fold lower than free pentamidine over a course of 110 four doses (30, 31) . However, the variability of the VSG molecules and underpinning 111 antigenic variation will almost certainly limit their effectiveness as targets for 112 therapeutic delivery. 113
114
Here we have developed a recombinant human anti-trypanosome-HpHbR antibody 115 conjugated to a PBD toxin, selected so that recognition of the trypanosome would be 116 independent of the VSG identity. This approach also strategically exploits advances 117 in anti-cancer ADC development. The antibody-PBD conjugate was effective at 118 killing trypanosomes in culture at picomolar concentrations whereas killing of human 119 cell lines required more than 100,000-fold higher concentrations. A single low dose 120 7 with either Trypanosoma brucei, Lister 427, HpHbR wild-type or HpHbR -/-cells in 146 culture for 2 hours in the presence of the lysosomal protease inhibitor FMK-024. A 147 control IgG1 with an unrelated specificity (NIP228) was used in parallel. 148
Internalisation was monitored by microscopy ( Figure 2 ) and at 10 nM IgG1 five of the 149 six HpHbR antibodies were endocytosed by wild-type cells but not by HpHbR-/-cells 150 and localised to a compartment consistent with the lysosome. There was no 151 internalisation of the control antibody in either cell line at 10 nM. Hence, five of the 152 antibodies were internalised by receptor mediated endocytosis demonstrating that 153 they recognised epitopes on HpHbR that are accessible on live cells. The sixth 154
HpHbR antibody (Tb086) showed limited internalisation and was not used further. 155 156
Toxin-conjugated HpHbR-targeting antibodies kill trypanosomes at picomolar 157 concentrations 158
The receptor-mediated endocytosis of these HpHbR antibodies was then exploited to 159 assess the effectiveness of ADCs against T. brucei in vitro. Two PBDs, SG3199 and 160 SG3552 (ref(36)) ( Figure 1B ), were used in these experiments; each was used as a 161 toxin-linker derivative, SG3249 and SG3376 respectively ( Figure 1B ), for antibody 162 conjugation. PBDs are DNA minor groove binding toxins (37-40) and were chosen as 163 trypanosomes have a highly complex mitochondrial genome formed from a network 164 of thousands of concatenated DNA circles and are consequently susceptible to DNA 165 binding toxins. This sensitivity is illustrated by the original patent on ethidium 166 bromide as a treatment for trypanosome infection and ethidium derivatives are still 167 used for animal trypanosomiasis (41, 42) . To assay for trypanocidal activity, cultures of T. brucei were incubated with a range 170 of concentrations of the anti-HpHbR-PBD conjugates over 48 hours. Growth was 171 measured as percentage proliferation compared to no treatment, with 0% relative to 172 controls representing no viable cells observed, and IC 50 values calculated. 173
174
Initial experiments were designed to identify the most effective HpHbR antibody and 175 used the PBD, SG3199. Free SG3199 had an IC 50 of ~1 pM ( Figure 3A , Table S1 ), 176 this confirmed its toxicity towards trypanosomes and indicated that it is freely cell 177 permeable. Prior to conjugation to the IgGs, SG3199 was modified by the addition of 178 a linker to facilitate conjugation and release in the lysosome after proteolysis to 179 produce SG3249(43) ( Figure 1B ). Free SG3249 had an IC 50 of ~240 pM ( Figure 3A , 180   Table S1 ); presumably the hydrophilic nature of the linker meant that cell access via 181 passive diffusion was reduced. Antibody-SG3249 conjugates were prepared for the 182 five HpHbR antibodies selected in the uptake experiment above and the NIP228 IgG 183 control, following IgG engineering to contain a surface exposed cysteine residue at 184 position 239 in the heavy chain CH2 domain for conjugation to PBD molecules(44) 185 ( Figure 1B) . The HpHbR antibody-SG3249 conjugates all killed trypanosomes with 186 IC 50 values between 9 and 86 pM compared to 2100 pM for the control NIP228-187 SG3249 conjugate ( Figure 3A and Table S1 ), demonstrating targeted cell killing by 188
HpHbR antibody-PBD conjugates. The two most potent antibodies were Tb074 and 189
Tb085 with IC 50 values of 17 and 9 pM respectively and they were selected for 190 further experiments. 191
192
The next set of experiments used PBD SG3552 and its linker-derivative SG3376 (45, 193 46) ( Figure 1B ). This toxin-linker combination was chosen as it was designed to have 194 9 fewer off-target effects (45, 47) and was shown to be more potent against 195 trypanosomes in preliminary experiments. Three antibody-SG3376 conjugates were 196 prepared from Tb074, Tb085 and NIP228 and all were tested for trypanocidal activity 197 as above but using HpHbR wild type and -/-cell lines ( Figure 3B and Table 1) . 198 SG3552 killed trypanosomes with IC 50 values of 0.14 pM in wild type and 0.2 pM in 199
HpHbR -/-cell lines; the addition of the linker to make SG3376 reduced the toxicity to 200 112 pM and 197 pM in wild type and -/-cell lines respectively, again presumably due 201 to the increase in hydrophilicity conferred by the linker reducing passive cell entry. 202
The antibody conjugates Tb085-SG3376 and Tb074-SG3376 were effective in killing 203 wild-type trypanosomes with IC 50 values of 0.3 pM and 1.3 pM respectively. In 204 contrast both were far less effective against HpHbR -/-cells with IC 50 values of 1390 205 pM and 3270 pM showing that the action of the ADC is dependent on HpHbR 206 expression. The action of the NIP228-SG3376 conjugate was unaffected by HpHbR 207 expression and had an IC 50 of 3750 pM and 3000 pM in HpHbR wild type and -/-208 cells respectively. Taken together these findings showed that HpHbR antibody-209 SG3376 conjugates are highly effective in killing trypanosomes through a 210 mechanism whereby the presence of the receptor increases specificity by several 211 thousand-fold over the action of non-specific antibody-SG3376 conjugates. To assess whether the HpHbR antibody-SG3376 conjugates have specificity for 231 trypanosomes over mammalian cells in culture, PBD toxin SG3552 and antibody-232 SG3376 conjugates were assessed for toxicity against a range of human cell lines. 233
SG3552 was toxic to all cell lines assayed at picomolar concentrations (S3 Figure) , 234 the most sensitive was the Jurkat cell lines with an IC 50 value of 19.6 pM, around 235 100-fold less-sensitive than the T. brucei cell lines (Table 1) . This was expected: 236 11 trypanosomes are particularly sensitive to many DNA damaging toxins as described 237
above. The NIP228-SG3376, Tb074-SG3376 and Tb085-SG3376 conjugates all had 238 IC 50 values that were conservatively estimated to be >50 000 pM (S3 Figure) . The 239
IC 50 values of the two HpHbR antibody-SG3376 conjugates for the human cell lines 240 was at least 50,000 times greater than those for trypanosomes (Table 1) . All infected mice had a total flux of between 2.5x10 9 and 5.9x10 9 p/s with the 255 exception of a single mouse which had a lower level of infection at 3x10 7 p/s. 256 Subsequent to imaging, on day 3, groups of five mice were then treated with (1) 0.25 257 mg/kg Tb085-SG3376 or (2) 0.25 mg/kg NIP228-SG3376 or (3) PBS alone. Three 258 uninfected mice were used as negative controls for the BLI. again no trypanosomes were detected in any tissue (S6 Figure) . Finally, both a blood 283 sample and a section of brain tissue from each of the five mice treated with Tb085-284 SG3376 were incubated in trypanosome culture medium for one month; in no case 285 13 were any trypanosomes then detected. Together, these observations and 286 measurements indicate that a single dose of Tb085-SG3376 was sufficient to cure 287 infection in 5/5 mice in the experimental group. 288 289
Discussion 290
African trypanosomes proliferate in the bloodstream and tissue spaces of their 291 mammalian hosts where they are continually exposed to the adaptive immune 292 response. The trypanosome cell surface is covered by a densely packed coat of 293 VSG that underpins persistence of infection by antigenic variation. The VSG coat 294 must be permissive for receptor mediated endocytosis of host macromolecules as 295 nutrients and here this has been exploited for the delivery of an ADC. The HpHbR 296
was chosen for this study as: (i) it is a natural route for uptake of the trypanolytic 297 factors (5), which kill sensitive trypanosomes strains in human serum; (ii) it is 298 accessible to ligands larger than IgG (5); (iii) it has a known structure (34, 35); (iv) 299
HpHbR null cell lines grow at a normal rate in culture (5, 34) and were an ideal 300 control for specificity of uptake. We found that HpHbR monoclonal antibodies are 301 taken up into HpHbR wild type cells but not HpHbR -/-cells, proving that receptors for 302 host macromolecules are accessible on live trypanosomes. These same antibodies 303 conjugated to a PBD were able to kill trypanosomes in culture at pM concentration in 304 a manner that was dependent on HpHbR expression. Significantly higher doses, realistic approach for development of therapeutics for trypanosome and other 320 protozoan infections. Amongst the key challenges in generating ADCs for 321 applications in oncology is ensuring minimal off-target toxicity and so, as well as 322 through ADC chemistry, low doses are desirable (reviewed in (54)). The single dose 323 of 0.25 mg/kg was selected in these experiments as a proof-of-concept because it is 324 at the lower end of effective oncological ADC treatment in mice(55) and is well below 325 the anticipated maximum tolerated dose (56). The minimum efficacious dose 326 achievable with the anti-HpHbR ADC was not tested in this study and it is likely that 327 the targeting of parasites will be achieved using lower doses than required for 328 oncology for two key reasons. First, in contrast to the surface of cancer cells, 329 parasite-specific surface receptors are entirely different from host cell surface 330 receptors leading to highly selective uptake of the antibody into the pathogen. 331
Second, the effectiveness of the ADC in this study was enhanced by the sensitivity 332 of trypanosomes to DNA-binding agents, in comparison to host cells. Together these 333 led to a 100,000-fold difference in toxicity between trypanosome and human cells in 334 15 vitro. These considerations will also apply to other protozoal pathogens providing a 335 suitable target can be identified. 336
337
Disease caused by T. brucei infection has two stages: in stage 1 trypanosomes are 338 excluded from the central nervous system (CNS) by the blood brain barrier (BBB) 339 while in stage 2 infections trypanosomes enter the CNS. In the experimental model 340
used here, we have tested the ability to clear a stage 1 infection. Would ADCs be 341 able to target trypanosomes in the CNS? While administered intravenous antibodies 342 are present in the CNS at less than 0.1% of the concentration in the blood in murine 343 models (57, 58) increased BBB permeability has been observed in murine models of 344 neurological-stage trypanosomiasis (59-61), which will increase the CNS 345 concentration of administered antibodies. Further, bifunctional fusion antibodies that 346 can cross the blood-brain barrier have been reported (57). Considerable resources are being used for the optimisation, assessment and clinical 359 trials of oncology ADCs. It is difficult to imagine such resources being available for 360 the developmental pipeline of therapeutics against protozoal pathogens that primarily 361 affect developing countries. Both cancer and protozoal pathogens are eukaryotic 362 cells and so the oncology-based strategies that take advantage of the cell biology of 363 cancer cells are often applicable to protozoa. Therefore, the scope for benefiting 364 from oncology developments is clear, particularly where the drug (such as PBDs, as 365 used in this study) do not deviate from oncology ADCs that are under development. 366
If simply modifying the epitope binding site can allow anti-cancer ADCs to be 367 repurposed then they could realistically be developed as a novel class of 368 therapeutics for protozoan pathogens. The cell surfaces of protozoan pathogens are 369 often particularly well studied due to the biological interest in their role in 370 host:parasite interactions and therefore the literature contains a reservoir of potential 371 targets (for example (64-68)). It is also worth noting that the production cost of ADCs 372 is far less than often realised (69-73). 373
374
In summary, we have demonstrated that a single dose of an ADC, shown to 375 specifically operate through the HpHbR was able to completely cure an infection in a 376 stage 1 trypanosomiasis model. These type of agents have the potential for 377 development for use to treat trypanosome infection in humans, and in the longer 378 term livestock animals. Furthermore, this work illustrates that developments in 379 oncology ADCs can be applied to protozoal pathogens, the causal agents of many 380 neglected diseases in need of new therapeutics. 381 382 383
Materials and Methods 384

Phage display selection of anti-HpHbR N-terminal domain single chain variable 385 fragments 386
Recombinant HpHbR N-terminal domain (NTD) was expressed as previously 387 described (34) and a scFv antibody library was used to perform soluble and panning 388 phage display selections (74). Briefly, panning selections were performed by coating 389 5 µg/mL biotinylated HpHbR NTD on to a single well of a streptavidin-coated 96-well 390 plate or 10 µg/mL non-biotinylated HpHbR NTD on to a single well of a Nunc 391
Maxisorp plate overnight at 4 o C. Coated wells were washed three times with 392 phosphate buffered saline (PBS) prior to incubation for 1hr at room temperature with 393 3% Marvel skimmed milk powder in PBS. Next, 1 x 10 12 phage particles in 6% Marvel 394 in PBS were added to each coated well and incubated for 1hr at room temperature. 395
The wells were washed five times with PBS containing 0.1% Tween-20 and five 396 times with PBS prior to elution and recovery of phage. For soluble selection, phage 397
were pre-incubated with magnetic beads in 3% Marvel in PBS at room temperature 398 for 1 hour. Subsequently, the magnetic beads were removed and the phage-399 containing supernatant was incubated with biotinylated HpHbR NTD at room 400 temperature for 1 hour. Streptavidin magnetic beads were subsequently added to the 401 reaction and incubated at room temperature for 5 minutes. The magnetic beads were 402 washed five times with 0.1% Tween-20 in PBS. For all selections, phage were eluted 403 with 10 µg/ml trypsin in PBS for 30 minutes at 37 o C. Exponentially grown TG1 E.coli 404 cells were infected with the eluted phage and grown overnight at 
Generation of full length human IgG1 and THIOMABS 426
Selected scFvs were converted to full length human IgG1s using standard molecular 427 biology techniques. Plasmids encoding secreted antibody (75) 
PBD conjugation to THIOMABs 435
The HpHbR THIOMABS and a NIP228 negative control were reduced by the 436 addition of a forty fold molar excess of tris(2-carboxyethyl)phosphine (TCEP) in PBS, 437 1 mM EDTA, pH 7.2 for 4 h at 37 o C. TCEP was subsequently removed and the 438 THIOMABS were re-oxidised with a twenty times molar excess of dehydroascorbic 439 acid for 4h at 25 o C. A ten times molar excess of toxin plus linker was added and 440 incubated for 1 h at 25 o C, the reactions were quenched by the addition of excess of 441 N-acetyl-L-cysteine. The resultant ADCs were formulated in PBS, pH 7.2 after 442 ultrafiltration to removed excess toxin. ADCs were characterized by determination of 443 monomeric purity by size exclusion chromatography (Table S2) , drug-antibody-ratio 444 (DAR) by RP-HPLC chromatography (Table S2) 
Internalisation of fluorescently labelled IgGs into live cells 453
For T. b. brucei uptake assays 1 x 10 6 cells per assay were incubated with 10 nM 454
Alexa Fluor 594-labelled IgG in 300µl HMI-9, 10% FCS, 2µM FMK-024 protease 455 inhibitor for 1.5 hours at 37°C. Cells were washed once in HMI-9, 10% FCS then 456 20 fixed in 1% PFA for 10 minutes at room temperature and resuspended in PBS. 457
Internalisation was determined by microscopy using a Zeiss Imager M1 microscope 458 and analysed with AxioVision Rel 4.8 software. 459
460
In vitro trypanosome cell-killing assays 461 T. b. brucei Lister 427 wild-type or HpHbR -/-cell lines were incubated at 1 x 10 4 462 cells/ml in triplicate with PBDs or ADCs for 48 hours before cells were counted and 463 growth was calculated relative to an untreated control for each cell line. All assays 464 contained 0.5% DMSO. Data were Log 10 transformed and nonlinear regression lines 465 of best fit and IC 50 values were calculated using GraphPad Prism 6. 466 467
CellTiter-Glo Luminescent Cell Viability Assay 468
In vitro viability cell assays were performed with primary and transformed human cell 469 lines: Raji (ECACC), Jurkat E6.1 (ATCC), NHLF (LONZA) and HUVEC (LONZA). 470
These cell lines were mycoplasma tested and authenticated by PCR using human 471 16-marker short tandem repeat profiling and interspecies contamination test by 472 IDEXX (Columbia, MO). Cells seeded at 2 x 10 5 cell/ml (Raji and Jurkat) and at 2 x 473 10 3 cell/ml (NHLF and HUVEC) in 96 well plates were incubated with the SG3552 474 toxin, the toxin+linker SG3376 and the corresponding ADCs (Tb074-SG3376, 475
Tb085-SG3376 and NIP228-SG3376). All assays contained 0.5% DMSO. After 96 476 hours, the number of viable cells in culture was measured using the CellTiter-Glo 2.0 477 luminescent cell viability assay and read in Envision plate reader. Growth was 478 calculated relative to an untreated control for each cell line. Data were Log 10 479 transformed and nonlinear regression lines of best fit and IC 50 values were 480 calculated, where possible using GraphPad Prism 6. 481 21 482
Mouse infection and bioluminescent imaging of trypanosome infection 483
Pleomorphic T. b. brucei GVR35-VSL2 bloodstream forms were cultured and 484 maintained at 37°C/5%CO 2 in HMI-9 medium supplemented with 20% FBS, 1μg/ml 485 puromycin and 1% methyl cellulose (33). Parasites were maintained at <1 x 10 6 ml -1 486 and were not cultured for more than three passages prior to mouse infection. 487
488
Mice were purchased from Charles River (UK). They were maintained under specific 489 pathogen-free conditions in individually ventilated cages with a 12 hour light/dark 490 cycle and access to food and water ad libitum. Female BALB/c mice aged 8 to 12 491 weeks were infected intraperitoneally with 3x10 4 T. b. brucei GVR35-VSL2 cells (33). 492
Three groups of five mice were infected. On day 3 post infection the mice were 493
imaged to obtain the pre-treatment infection level. Five mice received 0.25 mg/kg 494 Tb085-SG3376, five mice received PBS alone and five mice received 0.25 mg/kg 495 NIP288, all intravenously. A group of three mice was not infected. 496
497
Imaging was carried out by intraperitoneal injection of 150 mg/kg D-luciferin. After 5 498 minutes, mice were anaesthetised with 2.5% (v/v) gaseous isofluorane in oxygen. 499
The mice were transferred to the IVIS Illumina and imaged using LivingImage 4.3. 500 software (PerkinElmer). Exposure times were determined automatically and varied 501 between 0.5 s and 5 min depending on the radiance. After imaging, mice were 502 allowed to recover and transferred back to their cages. Millan CR, Acosta-Reyes FJ, Lagartera L, Ebiloma GU, Lemgruber L, Nue Martinez JJ, et al.
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Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein Three groups of 5 mice were infected with pleomorphic T. b. brucei GVR35-VSL2 775 cells (32, 33), which allow for parasite burden in live mice to be assessed over a time 776 course by bioluminescent imaging (BLI). BLI was performed prior to any treatment at 777 3 dpi and then at regular time points following treatment on 3 dpi with a single 778 intravenous dose of (1) 0.25 mg/kg Tb085-SG3376 (n=5), (2) given point on the image. Exposure times range from 0.5 seconds (for heavily 792 burdened mice) to 5 minutes (for uninfected animals). One mouse in the PBS control 793 group had a lower BLI signal than all other infected mice at 3 dpi (S5 Figure) . In the 794 image shown here this mouse appears negative, however, this is due to the low 795 exposure time required for adjacent mice. Tb074-SG3376, Tb085-SG3376) to mid-to-high nanomolar concentrations. Lines 814 represents nonlinear regression lines of best fit on Log 10 transformed data, although 815 it was not possible to fit accurate lines or calculate IC 50 values for the ADCs due to 816 lack of saturation of the cell killing assay. All assays were carried out in triplicate over 817 
